Table 1 Patient characteristics within subgroups
Variables | White patients N = 65,171(%) | Black patients N = 5175(%) | P value* |
|---|---|---|---|
Median follow-up (months) | 50 | 46 | |
Age at diagnosis (year) | P < 0.001 | ||
< 45 | 25,141(38.6) | 1936(37.4) | |
≥ 45 | 40,030(61.4) | 3239(62.6) | |
Sex | P < 0.001 | ||
Male | 15,013(23.0) | 867(16.8) | |
Female | 50,158(77.0) | 4308(83.2) | |
Histologic type | P < 0.001 | ||
CPTC | 40,383(62.0) | 2465(47.6) | |
FVPTC | 21,138(32.4) | 2145(41.4) | |
FTC | 3650(5.6) | 565(10.9) | |
Therapy | P < 0.001 | ||
Lobectomy | 8619(13.2) | 837(16.2) | |
Total thyroidectomy | 25,120(38.5) | 2223(43.0) | |
Total thyroidectomy and radioactive iodine | 31,432(48.2) | 2115(40.9) | |
Removal of lymph nodes | P < 0.001 | ||
0 | 31,931(49.0) | 3647(70.5) | |
1–3 | 17,412(26.7) | 940(18.2) | |
≥ 4 | 15,828(24.3) | 588(11.4) | |
Stage | P < 0.001 | ||
I | 48,079(73.8) | 3810(73.6) | |
II | 5418(8.3) | 538(10.4) | |
III | 8353(12.8) | 646(12.5) | |
IV | 3321(5.1) | 181(3.5) | |
Tumor size (mm) | P < 0.001 | ||
≤ 10 | 25,593(39.3) | 1977(38.2) | |
11–20 | 19,714(30.2) | 1203(23.2) | |
21–40 | 14,732(22.6) | 1210(23.4) | |
> 40 | 5132(7.9) | 785(15.2) | |
Median tumor size | 13 | 15 | |
Tumor extension | P < 0.001 | ||
Intrathyroidal | 55,294(84.8) | 4650(89.9) | |
Minimal extrathyroidal | 4274(6.6) | 203(3.9) | |
Gross extrathyroidal | 5603(8.6) | 322(6.2) | |
Lymph node metastases | P < 0.001 | ||
Negative | 52,459(80.5) | 4708(91.0) | |
Level VI | 7885(12.1) | 284(5.5) | |
Level I, II, III, IV, V, or VII | 4827(7.4) | 183(3.5) | |
Distant metastases | 0.074 | ||
None | 64,720(99.3) | 5128(99.1) | |
Yes | 451(0.7) | 47(0.9) | |
Insurance status | P < 0.001 | ||
None | 1202(1.8) | 185(3.6) | |
Insured | 46,236(70.9) | 3319(64.1) | |
Any Medicaid | 3925(6.0) | 617(11.9) | |
Unknown | 13,808(21.2) | 1054(20.4) | |
Status | P < 0.001 | ||
Alive | 62,459(95.8) | 4907(94.8) | |
Dead | 2712(4.2) | 268(5.2) | |
Thyroid cancer | 377(0.6) | 31(0.6) | |
Other | 2335(3.6) | 237(4.6) |